Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease

Abstract

This study characterizes expression of pharmacogenes across the histological NAFLD severity spectrum. Here, the authors show the downregulation of CYP2C19 in NAFLD which supports developing personalized medicine approaches for drugs sensitive to metabolism by the CYP2C19 enzyme.